ZNF582 overexpression restrains the progression of clear cell renal cell carcinoma by enhancing the binding of TJP2 and ERK2 and inhibiting ERK2 phosphorylation

Yang, Wuping; Zhang, Zedan; Li, Lei; Zhang, Kenan; Xu, Yawei; Xia, Mancheng; Zhou, Jingcheng; Gong, Yanqing; Chen, Jinchao; Gong, Kan

doi:10.1038/s41419-023-05750-y

Cited by 5 publications

(2 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some studies have also proposed that methylation of zinc finger protein 582 (ZNF582) could be employed to evaluate the clinical response in patients with LACC treated with CCRT ( 107 , 108 ). ZNF582 is a member of the family of zinc finger proteins that function as transcription factors and is involved in several cellular processes such as DNA damage response, proliferation and cell cycle regulation factors.…”

Section: Dna Methylation Markersmentioning

confidence: 99%

Promising predictive molecular biomarkers for cervical cancer (Review)

Lizano,

Carrillo‑García,

De La Cruz‑Hernández

et al. 2024

Int J Mol Med

View full text Add to dashboard Cite

Cervical cancer (CC) constitutes a serious public health problem. Vaccination and screening programs have notably reduced the incidence of CC worldwide by >80%; however, the mortality rate in low-income countries remains high. The staging of CC is a determining factor in therapeutic strategies: The clinical management of early stages of CC includes surgery and/or radiotherapy, whereas radiotherapy and/or concurrent chemotherapy are the recommended therapeutic strategies for locally advanced CC. The histopathological characteristics of tumors can effectively serve as prognostic markers of radiotherapy response; however, the efficacy rate of radiotherapy may significantly differ among cancer patients. Failure of radiotherapy is commonly associated with a higher risk of recurrence, persistence and metastasis; therefore, radioresistance remains the most important and unresolved clinical problem. This condition highlights the importance of precision medicine in searching for possible predictive biomarkers to timely identify patients at risk of treatment response failure and provide tailored therapeutic strategies according to genetic and epigenetic characteristics. The present review aimed to summarize the evidence that supports the role of several proteins, methylation markers and non-coding RNAs as potential predictive biomarkers for CC.

show abstract

Section: Dna Methylation Markersmentioning

confidence: 99%

Promising predictive molecular biomarkers for cervical cancer (Review)

Lizano,

Carrillo‑García,

De La Cruz‑Hernández

et al. 2024

Int J Mol Med

View full text Add to dashboard Cite

show abstract

“…Experimental data claimed that under-expression of ZNF582 markedly hindered apoptosis and promoted cell proliferation, migration, invasion, and adhesion of ccRCC [ 33 ]. It was further illustrated by Yang et al [ 34 ] that ZNF582 binds to tight junction protein 2 (TJP2) and up-regulates TJP2 protein expression. Elevated TJP2 protein combines with extracellular signal-regulated kinase 2 (ERK2) to promote ERK2 protein expression which suppresses the phosphorylation of ERK2, thereby inhibiting the growth and metastasis of ccRCC [ 34 ].…”

Section: Dna Methylation As Potential Non-invasive Biomarkers For Rccmentioning

confidence: 99%

Biomarkers in renal cell carcinoma and their targeted therapies: a review

Gupta,

Shamsher Singh

2023

Exploration of Targeted Anti-Tumor Therapy

View full text Add to dashboard Cite

Renal cell carcinoma (RCC) is one of the most life-threatening urinary malignancies displaying poor response to radiotherapy and chemotherapy. Although in the recent past there have been tremendous advancements in using targeted therapies for RCC, despite that it remains the most lethal urogenital cancer with a 5-year survival rate of roughly 76%. Timely diagnosis is still the key to prevent the progression of RCC into metastatic stages as well as to treat it. But due to the lack of definitive and specific diagnostic biomarkers for RCC and its asymptomatic nature in its early stages, it becomes very difficult to diagnose it. Reliable and distinct molecular markers can not only refine the diagnosis but also classifies the tumors into thier sub-types which can escort subsequent management and possible treatment for patients. Potential biomarkers can permit a greater degree of stratification of patients affected by RCC and help tailor novel targeted therapies. The review summarizes the most promising epigenetic [DNA methylation, microRNA (miRNA; miR), and long noncoding RNA (lncRNA)] and protein biomarkers that have been known to be specifically involved in diagnosis, cancer progression, and metastasis of RCC, thereby highlighting their utilization as non-invasive molecular markers in RCC. Also, the rationale and development of novel molecular targeted drugs and immunotherapy drugs [such as tyrosine kinase inhibitors and immune checkpoint inhibitors (ICIs)] as potential RCC therapeutics along with the proposed implication of these biomarkers in predicting response to targeted therapies will be discussed.

show abstract

Silenced LASP1 interacts with DNMT1 to promote TJP2 expression and attenuate articular cartilage injury in mice by suppressing TJP2 methylation

Lian

Cheng

Kang

et al. 2023

The Kaohsiung J of Med Scie

View full text Add to dashboard Cite

To investigate the regulatory mechanisms and effects of LIM and SH3 protein 1 (LASP1) on osteoarthritis (OA). IL‐1β was used to induce OA in cell models. Viability and apoptosis of chondrocytes were assessed. The expressions of tumor necrsis factor‐α (TNF‐α) and IL‐6 were measured by ELISA kit, and Quantitative reverse transcription polymerase chain reaction (qRT‐PCR) and Western blot were performed to test the expression of related proteins. The STRING database was used to predict the relationship between LASP1 and DNA methyltransferase 1 (DNMT1). The tight junction protein 2 (TJP2) and Gene Expression Omnibus data were analyzed for differential OA genes. Methylation‐specific PCR detected methylation of the TJP2 promoter region, and chromatin immunoprecipitation detected the enrichment of DNMT1 in the TJP2 promoter region. Safranin O‐Fast Green staining and hematoxylin and eosin staining were used to determine the OARSI score and evaluate the pathological conditions of the joint tissues. LASP1 was highly expressed in IL‐1β‐induced cell models. Silencing of LASP1 promoted chondrocyte proliferation and expression of Collagen II and Aggrecan and inhibited chondrocyte apoptosis, inflammatory factors, and matrix metalloprotein expression. TJP2 is weakly expressed in OA models, and LASP1 promotes methylation of the TJP2 promoter region by interacting with DNMT1. Silencing of LASP1 attenuated IL‐1β‐induced chondrocyte degeneration by promoting TJP2 expression. Similarly, silencing LASP1 promotes TJP2 expression to alleviate articular cartilage injury in mice with OA. Silencing of LASP1 inhibited the methylation of the TJP2 promoter region by interacting with DNMT1, thereby alleviating articular cartilage damage in OA mice.

show abstract

ZNF582 overexpression restrains the progression of clear cell renal cell carcinoma by enhancing the binding of TJP2 and ERK2 and inhibiting ERK2 phosphorylation

Cited by 5 publications

References 46 publications

Promising predictive molecular biomarkers for cervical cancer (Review)

Promising predictive molecular biomarkers for cervical cancer (Review)

Biomarkers in renal cell carcinoma and their targeted therapies: a review

Silenced LASP1 interacts with DNMT1 to promote TJP2 expression and attenuate articular cartilage injury in mice by suppressing TJP2 methylation

Contact Info

Product

Resources

About